JANADRIA-FESTIVAL
23.12.2018 14:48:05 CET | Business Wire | Press release
The National Festival of Heritage and Culture in Janadria, which began last Thursday, is a valuable opportunity to highlight the elements of the tangible and intangible cultural heritage of the Kingdom of Saudi Arabia on an international level. Mainly as the festival is the most important event of its kind in the world, as it attracts millions of lovers of heritage and originality from Saudi Arabia, the Arabian Gulf region and worldwide, with hundreds of local, Arab and international media who will be covering the various rich activities of the festival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181223005010/en/
The festival reflects unique cultures, traditions and behavior from every region of the Kingdom, where there are many dialects and customs represented. This is both in the heritage of the regions, or through the folk market where the ‘Katateeb’ (traditional schools), folk games and old tales all in a traditional setting reveal simplicity and the identity of society at the time.
Urban Heritage of the Regions
The festival highlights the distinctiveness of the various areas of Saudi Arabia and their urban heritage through showing the identity of each region, as well as the heritage elements of handicrafts, folk dishes and museums.
Folk market
The Folk Market is a forum that reflects the great diversity in Saudi folklore, with the allocation of shops and workshops for each craftsman from each region in the market, which is the first nucleus in the establishment of the festival since its inception. At the Folk Market everything is displayed in a panoramic way preserving the depth and diversity of culture in one place.
Handicrafts
The National Heritage and Culture Festival is keen to support craftsmen by choosing the handicrafts for each region according to special criteria and mechanisms. More than 300 handicrafts are scattered throughout the festival.
Al Warraq
Al Warraq is one of the handicrafts that have disappeared, and this year for the first time will be in the folk market, where the public will notice the artisans specialized in the binding of books and their preservation, while using simple craft tools such as thread, needle, scissors and glue.
Women's Activities
This year, women will participate in several activities aimed at handicrafts and productive families, as well as highlighting the role of people with special needs. There will also be professional courses for visitors.
The Traditional Farm
The Traditional Farm was the main source of livelihood for some and displayed will be the means of plowing and chanting that echoed from the farmers during their work.
Katateeb School (Traditional School)
On display will be an imitation of the Mutawa (the traditional teacher) and his students, with a courtyard next to the school for old folk games.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20181223005010/en/
Contact:
Pyramedia Reham Barakat reham.barakat@pyramedia.biz
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom